Impact of Drug Price Standard Revisions on Pharmaceutical Selling Price Ceilings and Business Performance
First written in FY2016. 9 of 22 entries say "Restated". Latest entry: FY2026.
Medipal Holdings moved to the "Worse" side of this theme in 2019, 1 year before the typical company in this theme (2020).
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
13 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「(2026 National Health Insurance drug price revision rate, on a drug-cost basis: ▲4.02%) National Health Insurance drug prices, which had generally been revised once every 2 years, have also been revised in interim years since fiscal 2021. If this results in lower selling prices to medical institutions and other customers, it may affect the performance and financial condition of the wholesale business for prescription pharmaceuticals and other products.」
The company newly disclosed a 4.02% reduction in the 2026 National Health Insurance drug price revision rate and specified the risk to performance from the continuation of interim-year revisions and lower selling prices. - FY2025-H1MaterialisedAnnual report
「Despite the negative impact of the National Health Insurance drug price revision in April 2024 and lower demand for COVID-19 treatments and related testing reagents, revenue increased due to higher demand for COVID-19 vaccines and HPV (human papillomavirus) vaccines, greater focus on growth products, increased sales through the hospital channel and the expansion of the Medisocket business.」
The company stated that the negative impact of the National Health Insurance drug price revision in April 2024 actually occurred in the wholesale business for prescription pharmaceuticals and other products during the current interim consolidated accounting period. - FY2024WorsenedAnnual report
「(2024 National Health Insurance drug price revision rate, on a drug-cost basis: ▲4.67%) National Health Insurance drug prices, which had generally been revised once every 2 years, have also been revised in interim years since fiscal 2021. If this results in lower selling prices to medical institutions and other customers, it may affect the performance and financial condition of the wholesale business for prescription pharmaceuticals and other products.」
The company specified the 2024 National Health Insurance drug price revision rate as a 4.67% reduction on a drug-cost basis and continues to disclose the risk of lower selling prices resulting from the continuation of interim-year revisions. - FY2023-Q1MaterialisedAnnual report
「Although the market for prescription pharmaceuticals and other products was affected by the National Health Insurance drug price reduction implemented in April 2022, the number of new COVID-19 cases declined and the impact of restrictions on visits to medical institutions gradually eased, resulting in slight growth from the same period of the previous year.」
The company states that the National Health Insurance drug price reduction in April 2022 actually affected the pharmaceutical market in the current quarter. Meanwhile, the market grew slightly year on year as restrictions on visits to medical institutions eased. - FY2022WorsenedAnnual report
「(National Health Insurance drug price revision rate accompanying the October 2019 consumption tax increase, on a drug-cost basis: ▲2.40%)(2020 National Health Insurance drug price revision rate, on a drug-cost basis: ▲4.38%)(2021 National Health Insurance drug price revision rate, on a drug-cost basis: not disclosed)(2022 National Health Insurance drug price revision rate, on a drug-cost basis: ▲6.69%) National Health Insurance drug prices, which had generally been revised once every 2 years, have also been revised in interim years since fiscal 2021. If this results in lower selling prices to medical institutions and other customers, it may affect the performance and financial condition of the wholesale business for prescription pharmaceuticals and other products.」
The company specified the 2022 National Health Insurance drug price revision rate as a 6.69% reduction and indicated that interim-year revisions would continue, creating a risk to performance from lower selling prices. - FY2022-Q1RestatedAnnual report
「Although the market for prescription pharmaceuticals and other products was affected by National Health Insurance drug price reductions, restrictions on visits to medical institutions due to COVID-19 gradually eased, and the market grew slightly compared with the same period of the previous year.」
The company states that, while the market was affected by National Health Insurance drug price reductions, restrictions on visits to medical institutions gradually eased and the market grew slightly year on year. The risk associated with National Health Insurance drug price revisions has not been withdrawn. - FY2021WorsenedAnnual report
「National Health Insurance drug prices, which had generally been revised once every 2 years, have also been revised in interim years since fiscal 2021. If this results in lower selling prices to medical institutions and other customers, it may affect the performance and financial condition of the wholesale business for prescription pharmaceuticals and other products.」
The system now provides for National Health Insurance drug price revisions in interim years as well from fiscal 2021, and the risk of an impact on performance from lower selling prices continues and has become more specific. - FY2021-Q2WorsenedAnnual report
「Sales of prescription pharmaceuticals and other products remained extremely difficult due to the impact of the National Health Insurance drug price reduction implemented on 1 April 2020, restrictions on visits to medical institutions amid concerns about a renewed spread of COVID-19, and a decline in the number of surgeries.」
Amid the continuing impact of the National Health Insurance drug price reduction in April 2020, restrictions on visits to medical institutions and a decline in the number of surgeries also contributed, and prescription pharmaceutical sales were described as being in an "extremely difficult" situation. - FY2021-Q1MaterialisedAnnual report
「Sales of prescription pharmaceuticals and other products remained difficult due to the impact of the National Health Insurance drug price reduction implemented on 1 April 2020 and restrictions on visits to medical institutions caused by the spread of COVID-19.」
The company states that the National Health Insurance drug price reduction on 1 April 2020 actually affected prescription pharmaceutical sales in the current quarter. - FY2020WorsenedAnnual report
「(2018 National Health Insurance drug price revision rate, on a drug-cost basis: ▲7.48%)(National Health Insurance drug price revision rate accompanying the October 2019 consumption tax increase, on a drug-cost basis: ▲2.40%)(2020 National Health Insurance drug price revision rate, on a drug-cost basis: ▲4.38%) National Health Insurance drug prices, which are generally revised once every 2 years, are scheduled to undergo revisions in interim years from fiscal 2021. If this results in lower selling prices to medical institutions and other customers, it may affect the performance and financial condition of the wholesale business for prescription pharmaceuticals and other products.」
After presenting specific historical National Health Insurance drug price revision rates, the company stated that interim-year revisions were also scheduled from fiscal 2021 and that the risk of lower selling prices could increase. - FY2020-Q3RestatedAnnual report
「Although sales of prescription pharmaceuticals and other products were affected by the National Health Insurance drug price revision implemented on 1 October 2019, sales remained firm due to growth in new drugs, including anticancer drugs.」
The company continues to state that the National Health Insurance drug price revision on 1 October 2019 actually affected pharmaceutical sales. Meanwhile, sales remained firm due to growth in new drugs. - FY2020-Q2MaterialisedAnnual report
「Although sales of prescription pharmaceuticals and other products were affected by customers holding back purchases ahead of the National Health Insurance drug price revision implemented on 1 October 2019, sales remained firm due to growth in new drugs, including anticancer drugs, and front-loaded demand associated with the increase in the consumption tax rate.」
The company states that customers holding back purchases ahead of the National Health Insurance drug price revision on 1 October 2019 actually affected pharmaceutical sales. - FY2019-Q3RestatedAnnual report
「During the first nine months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk to sales price caps and performance from revisions to the National Health Insurance drug price schedule. - FY2019-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk to sales price caps and performance from revisions to the National Health Insurance drug price schedule. - FY2019-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk to sales price caps and performance from revisions to the National Health Insurance drug price schedule. - FY2018RestatedAnnual report
「Prices established under the National Health Insurance drug price schedule are generally revised every 2 years based on surveys of prevailing market prices, and developments in these prices may affect the performance of the wholesale business for prescription pharmaceuticals and other products.」
The company continues to explain that National Health Insurance drug prices function as a cap on selling prices and that revisions made approximately every 2 years may affect performance. - FY2018-Q3RestatedAnnual report
「During the first nine months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk to sales price caps and performance from revisions to the National Health Insurance drug price schedule. - FY2018-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk to sales price caps and performance from revisions to the National Health Insurance drug price schedule. - FY2017-Q3WorsenedAnnual report
「Although the company actively pursued sales of generic drugs, for which demand is expanding, and new drugs, the market contracted because of the National Health Insurance drug price reduction implemented in April 2016 and the peaking of demand for hepatitis C treatments, resulting in difficult conditions.」
The company states that the market contracted while the impact of National Health Insurance drug price reductions continued and demand for hepatitis C treatments also peaked. - FY2017-Q2RestatedAnnual report
「Sales of prescription pharmaceuticals remained difficult, despite efforts focused on generic drugs, for which demand is expanding, and new drugs, due to the impact of the National Health Insurance drug price reduction implemented in April 2016 and declining sales as demand for hepatitis C treatments, which had expanded in the previous year, reached maturity.」
The company continues to refer to the impact of National Health Insurance drug price reductions and describes the sales environment as difficult. - FY2017-Q1MaterialisedAnnual report
「Although sales of prescription pharmaceuticals and other products were affected by the National Health Insurance drug price reduction implemented on 1 April 2016, sales remained at approximately the same level as in the same period of the previous year, partly because the company focused on selling generic drugs, for which demand is expanding, and products eligible for the new drug creation premium.」
The company states that the National Health Insurance drug price reduction implemented on 1 April 2016 had an actual impact on sales of prescription pharmaceuticals and other products. - FY2016First statedAnnual report
「Prices established under the National Health Insurance drug price schedule are generally revised every 2 years based on surveys of prevailing market prices, and developments in these prices may affect the performance of the wholesale business for prescription pharmaceuticals and other products.」
The company explains that National Health Insurance drug prices function as a cap on selling prices and that revisions made approximately every 2 years may affect performance.